​Changes to medical policy on Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®)

September 19, 2022

Effective October 17, 2022, Independence Blue Cross will update its medical policy on Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®) for both Commercial and Medicare Advantage members.

This policy will be updated to communicate the medical necessity criteria, including step therapy and dosing and frequency requirements, for the newly FDA-approved indication of generalized myasthenia gravis (gMG) for ravulizumab-cwvz (Ultomiris®).

For more information, view the Commercial and Medicare Advantage policy notifications, which were published on September 19, 2022.